Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 15, Issue 4, 2002, Pages 407-414

  Woodcock, A ^a   Williams, A ^a   Batty, L ^a   Masterson, C ^a   Rossetti, A ^b   Cantini, L ^b,c  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b CHIESI FARMACEUTICI S P A   (Italy)

^c Medical Department   (Italy)

Author keywords

BDP; CFC; HFA 134a; PD20

Indexed keywords

BECLOMETASONE DIPROPIONATE; BRONCHODILATING AGENT; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; METHACHOLINE; NEDOCROMIL SODIUM; NORFLURANE; PROPELLANT; SALBUTAMOL; THEOPHYLLINE DERIVATIVE;

ADULT; AGED; AROUSAL; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HOARSENESS; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; THRUSH; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADULT; AEROSOL PROPELLANTS; AEROSOLS; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BRONCHIAL HYPERREACTIVITY; CHLOROFLUOROCARBONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RESPIRATORY FUNCTION TESTS;

EID: 0036959209     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/08942680260473489     Document Type: Article

References (22)

1. Aubier, M. 2000. Air pollution and allergic asthma. Rev. Mal. Respir. 17:159-165.
2. Marguet, C., D. Feray, N. Bocquel, et al. 2000. Respiratory distress in pediatric admission and emergency services. Epidemiology and evaluation criteria. Arch. Pediatr. 7:4-9.
3. Global Initiative for Asthma. 1995. Global strategy for asthma management and prevention. NHLBI/WHO Workshop report. Publication number 95-3659.
4. D'Souza, S. 1995. Montreal protocol and essential use exemptions. J. Aerosol Med. 8:13-17.
5. Leach, C.L. 1995. Approaches and challenges to use freon propellant replacements. Aerosol Sci. Technol. 22: 328-334.
6. Noakes, T.J. 1995. CFCs, their replacements, and the ozone-layer. J. Aerosol Med. 8:3-7.
7. Alexander, D.J. 1995. Safety of propellants. J. Aerosol Med. 8:29-34.
8. Alexander, D.J., and S.E. Libretto. 1995. An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane). Hum. Exp. Toxicol. 14:715-720.
9. Harrison, L.I., D. Donnell, J.L. Simmons, et al. 1996. 28-day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects. J. Pharm. Pharmacol. 4:596-600.
10. Gross, G., J. Vanden Burgt, D. Donnell, et al. 1996. New formulation inhaled steroid achieves equivalent peak flow control with half the daily dose in moderate asthmatics. Eur. Respir. J. 9:P1623.
11. Thompson, P.J., R.J. Davies, W.F. Young, et al. 1998. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir. Med. 92:33-39.
12. Davies, R.J., P. Stampone, and B.J. O'Connor. 1998. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir. Med. 92:23-31.
13. Brambilla, G., D. Ganderton, R. Garzia, et al. 1999. Modulation of aerosol clouds produced by pressurized inhalation aerosols. Int. J. Pharm. 186:53-61.
14. Knops, A., and S. Bendahmane. 2000. Open, randomized, two-way crossover, comparative bioavailability study of two metered dose inhalers of beclomethasone dipropionate after single dose in 12 healthy male subjects (unpublished report).
15. Replacement of chlorofluorocarbons (CFCs) in metered dose inhalation products. CPMP note for guidance, III/5378/93.
16. Quanjer, P.H., G.J. Tammeling, J.E. Cotes, et al. 1993. Lung volumes and forced ventilatory flows. Eur. Respir. J. 6:5-40.
17. Yan, K., C. Salome, and A.J. Woolcock. 1983. Rapid method of measurement of bronchial responsiveness. Thorax 38:760-765.
18. Elashoff, J.D. 1995. nQuery Advisor User's Guide. Dixon Associates, Los Angeles, CA.
19. Leach, C. 1996. Enhanced drug delivery through reformulating MDIs with HFA propellants - drug deposition and its effect on preclinical and clinical programs. Respir. Drug Deliv. 5:133-144.
20. Dahl, R., N. Ringdal, S.M. Ward, et al. 1997. Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate. Br. J. Clin. Pract. 51:11-15.
21. -1) in patients with asthma. Respir. Med. 95:212-220.
22. Tonnel, A.B., J. Bons, M. Legendre, et al. 2000. Clinical efficacy and safety of fluticasone propionate 250 μg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. Respir. Med. 94:S29-S34.